ADG-116 is under clinical development by Adagene Suzhou and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ADG-116’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADG-116 is under development for the treatment of solid tumors including pancreatic cancer, ovarian cancer and renal cell carcinoma, relapsed and refractory non-Hodgkin's lymphoma, liver cancer, melanoma and colon cancer. The drug candidate is developed based on dynamic precision library platform (DPL). It is administered through intravenous route. It acts by targeting CTLA-4. The drug candidate is developed based on Neobody technology.
Adagene Suzhou overview
Adagene Suzhou (Adagene) is a biotechnology company which develops immune-oncology antibodies for the treatment of cancer. It is investigating ADG106, an agonist monoclonal antibody (mAb) to treat non-Hodgkin lymphoma and solid tumors. The company utilizes SAFEbody, a proprietary antibody masking technology which is activated only in disease tissues further reducing the spread of disease to the entire body and enhancing the therapeutic window for antibodies; and dynamic precision library (DPL) platform to advance antibody discovery. Adagene was funded by GP Healthcare Capital, Eight Roads Ventures, F-Prime Capital Partners, General Atlantic and other companies. The company has operations in San Francisco, California, the US. Adagene is headquartered in Suzhou, Jiangsu, China.
For a complete picture of ADG-116’s drug-specific PTSR and LoA scores, buy the report here.